deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT04446182

Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD (FLIGHT)

A Phase II Study of Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic Graft Versus Host Disease (GVHD)

Sponsor: Incyte Corporation

Conditions Chronic Graft-versus-host-disease
Interventions Extracorporeal Photopheresis (ECP) Itacitinib
Updated 11 times since 2020 Last updated: Jan 18, 2024 Started: Jan 29, 2021 Primary completion: Mar 29, 2022 Completion: Jan 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

PI left institution

Other terminated trials from Incyte Corporation

More terminations from Incyte Corporation

Other Chronic Graft-versus-host-disease trials with similar outcome

Browse all Chronic Graft-versus-host-disease trials

Listed as NCT04446182, this PHASE2 trial focuses on Chronic Graft-versus-host-disease and remains terminated or withdrawn. Sponsored by Incyte Corporation, it has been updated 11 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jul 2020 – ~Dec 2020 · 5 months · monthly snapshotNot Yet Recruiting~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshotNot Yet Recruiting~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshotNot Yet Recruiting~Mar 2021 – ~Nov 2021 · 8 months · monthly snapshotRecruiting~Nov 2021 – ~Jun 2022 · 7 months · monthly snapshotRecruiting~Jun 2022 – ~Feb 2023 · 8 months · monthly snapshotRecruiting~Feb 2023 – ~Feb 2024 · 12 months · monthly snapshotActive Not Recruiting~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Feb 2024 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  4. Feb 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jun 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

▶ Show 6 earlier versions

  1. Nov 2021 — Jun 2022 [monthly]

    Recruiting PHASE2

  2. Mar 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  3. Feb 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE2

  4. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE2

  5. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

  6. Jul 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Incyte Corporation
  • University of Utah
Data source: University of Utah

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations